We are live on
!
Find out more
ANI Pharmaceuticals
ANIP
ANIP
126 hedge funds and large institutions have $330M invested in ANI Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 33 increasing their positions, 50 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
13% more capital invested
Capital invested by funds: $293M → $330M (+$36.9M)
5% more funds holding
Funds holding: 120 → 126 (+6)
1.61% more ownership
Funds ownership: 57.3% → 58.92% (+1.6%)
34% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 50
58% less call options, than puts
Call options by funds: $726K | Put options by funds: $1.72M
Holders
126
Holders Change
+6
Holders Change %
+5%
% of All Funds
2.17%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
17
Increased
33
Reduced
50
Closed
10
Calls
$726K
Puts
$1.72M
Net Calls
-$990K
Net Calls Change
+$255K
Top Buyers
Top Sellers
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.17M |
| 3 |
BlackRock
New York
|
-$1.83M |
| 4 |
Goldman Sachs
New York
|
-$1.48M |
| 5 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$1.38M |
